Speakers
Rakesh Dixit
Chief Executive Officer & Founder
BioNavigen
Bill Mallet
Staff Scientist
Target Validation Bolt Bio
Day One
Monday 8 December, 2021
10:30 am | Every Antigen is a Target – If we Invent the Right Drug!
Christoffer Nielson
COO & Co-founder
Adcendo
Day One
Monday 8 December, 2021
10:00 am | Looking into Novel ADC Targets with Unique Properties
Earl Albone
Senior Director of Biochemistry & Bioanalytical Development
Eisai, Inc
Day Two
Tuesday 7th December, 2021
12:30 pm | Session Reserved for Eisai
Elaine Hurt
Director, Bioscience
AstraZeneca
Day Two
Tuesday 7th December, 2021
3:00 pm | Session Reserved for AstraZeneca
Greg Adams
Chief Scientific Officer
Elucida Oncology, Inc
Day Two
Tuesday 7th December, 2021
10:30 am | Development & Clinical Translation of ELU001, a Targeted Ultra- Small Topoisomerase 1 C’Dot Conjugate for the Treatment of Solid Tumors
Hans Peter Gerber
Chief Scientific Officer
3T Bioscionces
Day Two
Tuesday 7th December, 2021
4:00 pm | Identification of Novel pHLA Targets for Solid Tumor Targeting with ADCs
Jack Elands
Chief Executive Officer
Emergence Therapeutics
Day Two
Tuesday 7th December, 2021
10:00 am | Nectin-4, An Ideal ADC Target, or Maybe Not?
Jagath Reddy Junutula
Founder
Aarkus Therapeutics
Day One
Monday 8 December, 2021
3:30 pm | Chair’s Closing Remarks
10:00 am | Chair’s Opening Remarks
Day Two
Tuesday 7th December, 2021
4:30 pm | Chair’s Closing Remarks
10:00 am | Chair's Opening Remarks
John Lambert
Independent Consultant
Lenka Sadilkova
Director of Pharmacology
SOTIO
Day Two
Tuesday 7th December, 2021
11:00 am | SOT102, A Novel CLDN18.2-Targeting Antibody-Drug Conjugate With Strong Therapeutic Potential in Solid Tumors
Martha R. Neagu
Associate Medical Director
AbbVie
Day One
Monday 8 December, 2021
2:30 pm | Targeting EGFR Through ADCs
Regina Reilly
Oncology Discovery, Biologics & Research Fellow
AbbVie
Day Two
Tuesday 7th December, 2021
3:30 pm | Target Identification at the Intersection of Indication & Payload
Robert Lawrence
Senior Scientist
Seagen
Day Two
Tuesday 7th December, 2021
1:00 pm | Quantitative Proteomics Approaches for ADC Target Characterization
Seema Kantak
Vice President
Exelixis
Day One
Monday 8 December, 2021
12:00 pm | Target Expression & Warhead: The Driving Forces of ADC Activity
Terry Rabbits
Molecular Immunologist
ICR
Day One
Monday 8 December, 2021
3:00 pm | Targeting Leukaemias with Anti-CD7 Antibody & ADC
Tracy Kuo
Senior Director - Biology & Translational Science
Tallac Therapeutics
Day One
Monday 8 December, 2021